Impact of cancer supportive care pathways compliance on emergency department visits and hospitalizations

Journal of Oncology Practice

Volumn 10, Issue 3, 2014, Pages 168-173

  Kreys, Eugene D ^a,b   Kim, Ted Y ^a,b   Delgado, Andrew ^a,b   Koeller, Jim M ^a,b  

^a UNIVERSITY OF TEXAS AT AUSTIN   (United States)

^b UNIVERSITY OF TEXAS HEALTH SCIENCE CENTER AT SAN ANTONIO   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIANEMIC AGENT; ANTIEMETIC AGENT; APREPITANT; CARBOPLATIN; CISPLATIN; CYCLOPHOSPHAMIDE; DEXAMETHASONE; GRANULOCYTE COLONY STIMULATING FACTOR; HEMOGLOBIN; OXALIPLATIN; PALONOSETRON; ANTINEOPLASTIC AGENT;

AMBULATORY CARE; ANEMIA; ARTICLE; BREAST CANCER; CANCER CHEMOTHERAPY; CANCER SUPPORTIVE CARE; CANCER THERAPY; CHEMOTHERAPY INDUCED NAUSEA AND VOMITING; COLORECTAL CANCER; COMPARATIVE STUDY; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG COST; DRUG DOSE TITRATION; DRUG UTILIZATION; EMERGENCY WARD; FEMALE; HEALTH CARE UTILIZATION; HEMOGLOBIN BLOOD LEVEL; HOSPITALIZATION; HOSPITALIZATION COST; HUMAN; LUNG CANCER; MAJOR CLINICAL STUDY; MALE; MEDICAL RECORD REVIEW; MEDICATION COMPLIANCE; NEUTROPENIA; BREAST NEOPLASMS; CHEMICALLY INDUCED; COLORECTAL NEOPLASMS; ECONOMICS; EMERGENCY HEALTH SERVICE; LUNG NEOPLASMS; PALLIATIVE THERAPY; RETROSPECTIVE STUDY; STATISTICS AND NUMERICAL DATA;

ANTINEOPLASTIC AGENTS; BREAST NEOPLASMS; COLORECTAL NEOPLASMS; EMERGENCY SERVICE, HOSPITAL; GRANULOCYTE COLONY-STIMULATING FACTOR; HEMATINICS; HOSPITALIZATION; HUMANS; LUNG NEOPLASMS; MEDICATION ADHERENCE; NEUTROPENIA; PALLIATIVE CARE; RETROSPECTIVE STUDIES;

EID: 84907065779     PISSN: 15547477     EISSN: 1935469X     Source Type: Journal    
DOI: 10.1200/JOP.2014.001376     Document Type: Article

References (33)

1. National Cancer Institute: SEER survival monograph: Cancer survival among adults-US SEER program, 1988- 2001, patient and tumor characteristics. http://seer.cancer.gov/publications/survival/
2. National Institutes of Health: NIH fact sheets: Cancer. http://report.nih.gov/nihfactsheets/viewfactsheet.aspx?csid-75
3. ASCO CancerProgress.net: Progress against cancer. http://www.cancerprogress. net/timeline/major-milestones-against-cancer
4. Groopman JE, Itri LM: C hemotherapy-induced anemia in adults: Incidence and treatment. J Natl Cancer Inst 91:1616-1634, 1999
5. Caggiano V, Weiss RV, Rickert TS, et al: Incidence, cost, and mortality of neutropenia hospitalization associated with chemotherapy. Cancer 103:1916- 1924, 2005
6. Dale DC, McCarter GC, Crawford J, et al: Myelotoxicity and dose intensity of chemotherapy: Reporting practices from randomized clinical trials. J Natl Compr Canc Netw 1:440-454, 2003
7. Burke TA, Wisniewski T, Ernst FR: Resource utilization and costs associated with chemotherapy-induced nausea and vomiting (CINV) following highly or moderately emetogenic chemotherapy administered in the US outpatient hospital settin g. Support Care Cancer 19:131- 140, 2011
8. Kuderer NM, Dale DC, Crawford J, et al: Impact of primary prophylaxis with granulocyte colony-stimulating factor on febrile neutropenia and morta lity in adult cancer patients receiving chemotherapy: A systematic review. J Clin Oncol 25: 3158-3167, 2007
9. Witzig TE, Silberstein PT, Loprinzi CL, et al: Phase III, randomized, doubleblind st udy of epoetin alfa compared with placebo in anemic patients receiving chemotherapy. J Clin Oncol 23:2606-2617, 2005
10. Jordan K, Sippel C, Schmoll HJ: Guidelines for antiemetic treatment of chemoth erapy-induced nausea and vomiting: Past, present, and future recommendations. Oncologist 12:1143-1150, 2007
11. Coates A, Abraham S, Kaye SB, et al: On the receiving end-patient perception of the side-effects of cancer chemotherapy. Eur J Cancer Clin Oncol 19:203-208, 1983
12. Leyland-Jones B, BEST Investigators and Study Group: Breast cancer trial with erythropoietin terminated unexpectedly. Lancet Oncol 4:459-460, 2003
13. Wright JR, Ung YC, Julian JA, et al: Randomized, double-blind, placebocontrolled trial of erythropoietin in non-small-cell lung cancer with disease-related anem ia. J Clin Oncol 25:1027-1032, 2007
14. National Comprehensive Cancer Network: Clinical practice guidelines in oncology. http://www.nccn.org/professionals/physician-gls/f-guidelines.asp
15. European Organisation of Research and Treatment of Cancer: Clinical guidelines. http://www.eortc.org/investigators-area/eortc-guidelines
16. American Society of Clinical Oncology: Clinical guidelines. http://www.asco.org/quality-guidelines/guidelines
17. de Vries M, van Weert JC, Jansen J, et al: Step by step development of clinical care pathways for older cancer patients: Necessary or desirable? Eur J Cancer 43:2170-2178, 2007
18. Pearson SD, Goulart-Fisher D, Lee TH: Critical pathways as a strategy for improving care: Problems and potential. Ann Intern Med 123:941-948, 1995
19. Rotter T, Kinsman L, James E, et al: The effects of clinical pathways on professional practice, patient outcomes, length of stay, and hospital costs: Cochrane systematic review and meta-analysis. Eval Health Prof 35:3-27, 2011
20. Kreys ED, Koeller JM: Documenting the benefits and cost savings of a large multistate cancer pathway program from a payer's perspective. J Oncol Pract 9:e241-7, 2013
21. Krzyzanowska MK, Treacy J, Maloney B, et al: Development of a patient registry to evaluate hospital admissions related to chemotherapy toxicity in a community cancer center. J Oncol Pract 1:15-19, 20 05
22. Kreys ED,Koeller JM: Documenting the benefits and cost savings of a large multistate cancer pathway program from a payer's perspective. J Oncol Pract 2013:e241-247.
23. Stewart DJ, Dahr ouge S, Coyle D, et al: Costs of treating and preventing nausea and vomiting in patients receiving chemotherapy. J Clin Oncol 17:344-351, 1999
24. Lin SJ, Hatoum HT, Buchner D, et al: Impact of 5-HT3 receptor antagonists on chemotherapy-induced nausea and vomiting: A retrospective cohort study. BMC Health Serv Res 12:215-6963-12-215, 2012
25. Rajan SS, Lyman GH, Stearns SC, et al: Effect of primary prophylactic granulocyte-colony stimulating factor use on incidence of neutropenia hospitalizations for elderly early-stage breast cancer patients receiving chemotherapy. Med Care 49:649 -657, 2011
26. Rivera E, Erder MH, Moore TD, et al: Targeted filgrastim support in patients with early-stage breast carcinoma: Toward the implementation of a risk model. Cancer 98:222-228, 2003
27. Vogel CL, Wojtukiewicz MZ, Carroll RR, et al: First and subsequent cycle use of pegfilgrastim prevents febrile neutropenia in patients with breast cancer: A multicenter, double-blind, placebo-controlled phase III study. J Clin O ncol 23: 1178-1184, 2005
28. Clark OA, Lyman GH, Castro AA, et al: Colony-stimulating factors for chemotherapy-induced febrile neutropenia: A meta-analysis of randomized controlled trials. J Clin Oncol 23:4198-4214, 2005
29. Aapro M, Molassiotis A, Dicato M, et al: The effect of guideline-consistent antiemetic therapy on chemotherapy-induced nausea and vomiting (CINV): The pan european em esis registry (PEER). Ann Oncol 23:1986-1992, 2012
30. Giilmore JW, Walker Peacock N, Gu A, et al: Antiemetic guideline consistency and incidence of chemotherapy-induced nausea and vomiting (CINV) in U. S. community oncology practice: INSPIRE study. J Clin Oncol 30, 2012 (suppl; abstr 167)
31. Gascon P: Safety update on erythropoiesis-stimulating agents: Trials within and outside the accepted indications. Oncologist 13:4-10, 2008 (suppl 3)
32. Naeim A, Friedman L, Pasta DJ, et al: Prophylaxis of chemotherapy-induced neutropenia: Patterns of care in U.S. community oncology practices. J Clin Oncol 25, 2007 (suppl 18; abstr 9123)
33. Potosky AL, Malin JL, Kim B, et al: Use of colony-stimulating factors with chemotherapy: Opportunities for cost savings and improved outcomes. J Natl Cancer Inst 103:979 -982, 2011